

October 25, 2016

Exchange Notice

Flexible Derivatives Products 17/16

Anticipated adjustment due to share distribution in Karo Pharma

The following information is based on a press release from Karo Pharma AB (Karo Pharma) published on October 24, 2016 and may be subject to change.

Oasmia Pharmaceutical AB (Oasmia) is acquiring Karo Pharma's cancer project KB9520, paid in the form of newly issued shares in Oasmia. The board of Karo Pharma has decided to distribute the Oasmia shares to their shareholders. The conditions are yet to be determined. Provided that the regulatory conditions are fulfilled, NASDAQ Derivatives Markets will carry out a re-calculation of options, forwards and futures in Karo Pharma (KAROB).

Re-calculation of stock options, forwards and futures

Conditions	TBD
Ex-date	TBD
Re-calculation method	Provided that Oasmia is listed on the ex-date, the Basket Method will be applied. The new Contract shall consist of Karo Pharma shares as well as Oasmia shares in accordance with the conditions of the share distribution. The Settlement value of the Basket contract will be the combined value of the underlying shares
New exercise and forward/futures price	The exercise price and forward/future price will not be affected at the time the Contract is re-calculated to a Basket Contract.
New contract size	TBD
Date of re-calculation	TBD
Rules and Regulations of NASDAQ Derivatives Markets	3.5.3.5, 3.5.2.2



Further information regarding the re-calculation of the options, forwards and futures contracts will be published as soon as further information is available.

Members are encouraged to ensure that clients are aware of the above-mentioned adjustment.

For further information concerning this exchange notice please contact Elin Holmström or Andreas Karlsson, telephone + 46 8 405 60 00.

NASDAQ Derivatives Markets

Elin Holmström
Product Management

Andreas Karlsson
Product Management